We are live on ! Find out more
BAMS

Bellevue Asset Management (Switzerland) Portfolio holdings

AUM $656M
1-Year Est. Return 11.45%
This Fund
S&P 500
This Quarter Est. Return
-14.54%
1 Year Est. Return
+11.45%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$613M
AUM Growth
-$108M
Cap. Flow
+$11.4M
Cap. Flow %
1.86%
Top 10 Hldgs %
30.19%
Holding
150
New
11
Increased
47
Reduced
31
Closed
17

Top Buys

Rank Stock Value
1
SUPN icon
Supernus Pharmaceuticals
SUPN
+$5.95M
2
LRMR icon
Larimar Therapeutics
LRMR
+$3.76M
3
AMGN icon
Amgen
AMGN
+$3.65M
4
INSY
Insys Therapeutics, Inc.
INSY
+$3.31M
5
HALO icon
Halozyme
HALO
+$3.1M

Top Sells

Rank Stock Value
1
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$6.46M
2
CAH icon
Cardinal Health
CAH
+$3.59M
3
KITE
Kite Pharma, Inc.
KITE
+$3.49M
4
MDVN
MEDIVATION, INC.
MDVN
+$3.47M
5
ALKS icon
Alkermes
ALKS
+$3.33M

Sector Composition

Rank Sector Weight
1 Healthcare 91.86%
2 Financials 0.95%
3 Industrials 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WMGI
126
DELISTED
Wright Medical Group Inc
WMGI
$210K 0.03%
10,000
– –
XOMA
127
DELISTED
Xoma
XOMA
$169K 0.03%
11,250
-3,500
-24% -$110K
TTPH
128
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$164K 0.03%
1,100
+500
+83% +$367K
TBPH icon
129
Theravance Biopharma
TBPH
$876M
$126K 0.02%
11,428
– –
GERN icon
130
Geron
GERN
$949M
$124K 0.02%
45,000
– –
EIGR
131
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$53K 0.01%
111
-56
-34% -$29.7K
AST
132
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
$7K ﹤0.01%
1,875
– –
LCTX icon
133
Lineage Cell Therapeutics
LCTX
$286M
$2K ﹤0.01%
+2,842
New +$7.36K
CERS icon
134
Cerus
CERS
$508M
– –
-46,520
Closed -$241K
DHR icon
135
Danaher
DHR
$147B
– –
-28,269
Closed -$1.63M
PBYI icon
136
Puma Biotechnology
PBYI
$449M
– –
-3,000
Closed -$350K
SGMO
137
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-50,000
Closed -$555K
TNDM icon
138
Tandem Diabetes Care
TNDM
$1.59B
– –
-5,000
Closed -$542K
ABMD
139
DELISTED
Abiomed Inc
ABMD
– –
-10,000
Closed -$657K
IMMU
140
DELISTED
Immunomedics Inc
IMMU
– –
-300,000
Closed -$1.22M
MDSO
141
DELISTED
Medidata Solutions, Inc.
MDSO
– –
-10,000
Closed -$543K
ATHN
142
DELISTED
Athenahealth, Inc.
ATHN
– –
-8,000
Closed -$917K
TSRO
143
DELISTED
TESARO, Inc.
TSRO
– –
-10,300
Closed -$606K
BTX.WS
144
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
– –
-2,294
Closed -$3K
ENTL
145
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
– –
-20,000
Closed -$517K
PRXL
146
DELISTED
Parexel International Corp
PRXL
– –
-5,000
Closed -$322K
GI
147
DELISTED
EndoChoice Holdings, Inc.
GI
– –
-22,056
Closed -$361K
RLYP
148
DELISTED
RELYPSA INC COM
RLYP
– –
-15,000
Closed -$496K
THOR
149
DELISTED
THORATEC CORPORATION
THOR
– –
-55,000
Closed -$2.45M
RCPT
150
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
– –
-34,000
Closed -$6.46M
2 3 4 5
6

Similar funds

VFAM
Valley Forge Asset Management King Of Prussia, Pennsylvania $645M AUM 5.8% 1-Year Est. Return
MSU
Maple Securities USA Jersey City, New Jersey $672M AUM 1.03% 1-Year Est. Return
PSI
Pinnacle Summer Investments Fairfax, Virginia $678M AUM 9.5% 1-Year Est. Return
SFP
Santa Fe Partners Santa Fe, New Mexico $608M AUM 8.76% 1-Year Est. Return
MCM
Mazama Capital Management Portland, Oregon $544M AUM 9.52% 1-Year Est. Return
NMIS
Northwestern Mutual Investment Services Milwaukee, Wisconsin $525M AUM 2.45% 1-Year Est. Return
SM
Stratton Management King Of Prussia, Pennsylvania $824M AUM 1.57% 1-Year Est. Return
ZAM
Zenit Asset Management Stockholm, Sweden $450M AUM 8.32% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s Q3 2015 Portfolio in Review

As of Q3 2015, Bellevue Asset Management (Switzerland) held 150 positions worth $613M, down 15% from $721M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Asset Management (Switzerland)'s Q3 2015 filing shows 11 new, 47 increased, 31 reduced and 17 closed positions. Its largest new stake was Supernus Pharmaceuticals: 320,000 shares worth $4.49M. The largest sale was RECEPTOS INC COM STK (DE), an estimated $6.46M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 90% a quarter earlier, followed by Financials and Industrials.

  • Bellevue Asset Management (Switzerland)'s largest Q3 2015 buy was Supernus Pharmaceuticals: 320,000 shares worth $4.49M.
  • Bellevue Asset Management (Switzerland) added most to Amgen in Q3 2015, an estimated $3.65M increase.
  • Bellevue Asset Management (Switzerland)'s biggest Q3 2015 reduction was Cardinal Health, cutting an estimated $3.59M.
  • Bellevue Asset Management (Switzerland) fully exited RECEPTOS INC COM STK (DE) in Q3 2015, selling an estimated $6.46M.
  • Bellevue Asset Management (Switzerland)'s ten largest holdings make up 30% of its $613M portfolio in Q3 2015.
  • Bellevue Asset Management (Switzerland) opened 11 new positions and closed 17 in Q3 2015.
  • Bellevue Asset Management (Switzerland)'s portfolio value fell 15% quarter-over-quarter to $613M.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q3 2015, filed 12 Nov 2015.